Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EE-ASI-1: C19-A3 GNP in Type 1 Diabetes
NCT02837094Phase 1Completed
- Sponsor
- Cardiff University
- Start
- Sep 2016
- Primary completion
- Dec 2019
- Modality
- Prophylactic Vaccines, Nanoparticles, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C19-A3 GNP in type 1 diabetes mellitus (T1D), sponsored by Cardiff University. Primary endpoint: General safety and induction of hypersensitivity at 4 months. Started Sep 2016; status: completed.
02
Drugs
C19-A3 GNP
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02837094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837094.